Next Generation Sequencing: benefit analysis to support a strategic adoption model in the Italian NHS

November 12, 2018


  • Marco Volpe


  • Jean Marie Franzini


The evolution of tumor genomic profiling in personalized medicine requires a strategic management of genetic testing. Among the available technologies, Next Generation Sequencing (NGS), allows simultaneous testing for a wide range of genes. However NGS test benefits still need to be assessed and compared to the single-gene test (SGT) approach to provide recommendations for a strategic adoption in the Italian NHS setting.

The study aims to assess the differential impact of NGS and single-gene tests on the diagnostic-therapeutic process of patients with advanced non-small-cell lung cancer (aNSCLC) in a selection of Italian hospitals. On this purpose, we designed a decision model structured in two arms, SGT and NGS approaches, and three stages i.e. diagnostic biopsy, genetic testing and therapy initiation.

Related Industries

Get in touch

Are you ready to make sense and make things?